Core Viewpoint - The company, Hongyuan Pharmaceutical, reports that the production and sales of sodium hexafluorophosphate are currently stable and balanced, with plans to adjust production capacity based on future market demand [2]. Group 1: Production and Sales - The production and sales of sodium hexafluorophosphate are normal and balanced [2]. - The company has a designed production capacity of 400 tons per year for sodium hexafluorophosphate [2]. Group 2: Market Outlook - The market for sodium hexafluorophosphate is expected to expand due to the price advantages highlighted by the recovery of the lithium hexafluorophosphate market [2]. - The company is prepared to adjust and increase production capacity if there is significant growth in market demand in the future [2].
宏源药业：目前公司六氟磷酸钠产品生产和销售正常，产销均衡，现有设计产能400吨/年